MNS

MNS (NSC 170724), the beta-nitrostyrene derivative, is an orally active tyrosine kinase inhibitor and a broad-spectrum antiplatelet agent. MNS inhibits Src, Syk, and FAK with IC50 of 27.3, 2.8, and 97.6 μM, respectively. MNS inhibits NLRP3 inflammasome and β1 integrin. MNS completely inhibits U46619, ADP-, arachidonic acid-, collagen-, and thrombin-induced platelet aggregation with IC50 values of 2.1, 4.1, 5.8, 7.0, and 12.7 μM, respectively. MNS is cytotoxic to a variety of cells[1][2][3][4][5][6][7][8][9].

1485-00-3

NSC 170724; 5- (2-Nitrovinyl) benzodioxole

12352005

H301, H315, H319, H335

Integrin; NOD-like Receptor (NLR) ; Src; Syk

Reference compound

Cytoskeleton; Immunology/Inflammation; Protein Tyrosine Kinase/RTK

Cancer-Kinase/protease

Cancer

https://www.medchemexpress.com/MNS.html

10mM

99.60

DMSO : 50 mg/mL (ultrasonic) |H2O : < 0.1 mg/mL

O=[N+]([O-])/C=C/C1=CC(OCO2)=C2C=C1

C9H7NO4

193.16

H301, H315, H319, H335

[1]Wang WY, et al. Synthesis and pharmacological evaluation of novel beta-nitrostyrene derivatives as tyrosine kinase inhibitors with potent antiplatelet activity. Biochem Pharmacol. 2007;74 (4) :601-611.|[2]Wang WY, et al. Prevention of platelet glycoprotein IIb/IIIa activation by 3,4-methylenedioxy-beta-nitrostyrene, a novel tyrosine kinase inhibitor. Mol Pharmacol. 2006;70 (4) :1380-1389.|[3]Pettit RK, et al. E-Combretastatin and E-resveratrol structural modifications: antimicrobial and cancer cell growth inhibitory beta-E-nitrostyrenes. Bioorg Med Chem. 2009 Sep 15;17 (18) :6606-12.|[4]Chen IH, et al. 3,4-Methylenedioxy-β-nitrostyrene inhibits adhesion and migration of human triple-negative breast cancer cells by suppressing β1 integrin function and surface protein disulfide isomerase. Biochimie. 2015 Mar;110:81-92.|[5]He Y, et al. 3,4-methylenedioxy-β-nitrostyrene inhibits NLRP3 inflammasome activation by blocking assembly of the inflammasome. J Biol Chem. 2014 Jan 10;289 (2) :1142-50.|[6]Messerschmitt PJ, et al. Osteosarcoma Phenotype Is Inhibited by 3,4-Methylenedioxy-β-nitrostyrene. Sarcoma. 2012;2012:479712.|[7]Xiao M, et al. 3,4-Methylenedioxy-β-Nitrostyrene Ameliorates Experimental Burn Wound Progression by Inhibiting the NLRP3 Inflammasome Activation. Plast Reconstr Surg. 2016 Mar;137 (3) :566e-575e.|[8]Zheng J, et al. 3,4-Methylenedioxy-β-Nitrostyrene Alleviates Dextran Sulfate Sodium-Induced Mouse Colitis by Inhibiting the NLRP3 Inflammasome. Front Pharmacol. 2022 Jun 15;13:866228.|[9]Uysal E, et al. Targeting the PANoptosome with 3,4-Methylenedioxy-β-Nitrostyrene, Reduces PANoptosis and Protects the Kidney against Renal İschemia-Reperfusion Injury. J Invest Surg. 2022 Nov-Dec;35 (11-12) :1824-1835.

Room Temperature

-20°C, 3 years; 4°C, 2 years (Powder)

Reference compound1

No Development Reported